✦ LIBER ✦

Group therapy for nonorgasmic women: Two age levels

✍ Scribed by Barbara Schneidman; Linda McGuire

Publisher: Springer US
Year: 1976
Tongue: English
Weight: 491 KB
Volume: 5
Category: Article
ISSN: 0004-0002
DOI: 10.1007/bf01541375

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy groups for women sexually molest

Therapy groups for women sexually molested as children

✍ Mavis Tsai; Nathaniel N. Wagner 📂 Article 📅 1978 🏛 Springer US 🌐 English ⚖ 645 KB

A model for group therapy with latency-a

A model for group therapy with latency-age boys

✍ Marvin W. Clifford 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 666 KB

Model for crisis intervention through gr

Model for crisis intervention through group therapy for women with breast cancer

✍ Ora Gilbar 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 759 KB

Therapeutic factors in short-term group

Therapeutic factors in short-term group therapy for women with bulimia

✍ Hobbs, Michael ;Birtchnell, Sandra ;Harte, Anne ;Lacey, Hubert 📂 Article 📅 1989 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 680 KB

Group therapies for rheumatoid arthritis

Group therapies for rheumatoid arthritis: A controlled study of two approaches

✍ Gordon D. Strauss; Jane Sinden Spiegel; Marcia Daniels; Timothy Spiegel; John La 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 582 KB

An important unanswered question about rheumatoid arthritis (RA) is how the patient's psychological or emotional state relates to disease activity and functional status. No controlled studies of psychotherapeutic interventions in RA have been reported. To test the hypothesis that a psychosocial inte

A randomized Phase II trial of two dosag

A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

✍ James N. Ingle; Patricia A. Johnson; Vera J. Suman; James B. Gerstner; James A. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

letrozole dosage levels, 0.5 mg and 2.5 mg per day, was performed. Eligibility requirements included failure on two prior hormonal therapies and measurable